HS-131, a near-infrared dye-conjugated Hsp90 inhibitor, effectively identifies oncogene-driven breast cancers across various molecular subtypes.

Immunofluorescence[1]Cell Line: Tumor cells. Concentration: 10 μM. Incubation Time: 30 min. Result: Tissues/organs, including eyes, brain, heart, lung, liver, spleen, kidney, gut, urinary bladder and skin, were imaged ex vivo by the IVIS imager machine, an imaging modality that detects IR at 640 nm.

HS131 (10 nmol/mouse) could label breast cancers with different molecular subtypes, including MCF-7 and T-47D for luminal type, BT474M1 and KPL-4 for HER2+ subtype, MDA-MB-231 and MDA-MB-468 for triple negative subtype were chosen after considering the tumorigenic capacities of breast cancer cell lines in SCID mice[1]. Animal Model: SCID-beige mice bearing human breast cancer xenografts of different molecular

subtypes[1]. Dosage: 10 nmol/mouse. Administration: Injected intravenously. Result: All breast cancer xenografts with different molecular subtypes showed stronger nIR signals in tumor by intravenous administration of HS131 compared to HS152, and the retention of the nIR signals was detectable even at the 24 h time point in HS131 injected mice.